UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 124

Sortiert nach

Trastuzumab: updated mechanisms of action and resistance in breast cancer

Frontiers in oncology, 2012, Vol.2, p.62-62

2012

Volltextzugriff (PDF)

Long road towards effective HER3 targeting in breast cancer

Cancer treatment reviews, 2024-09, Vol.129, p.102786, Article 102786

2024

Volltextzugriff (PDF)

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Annals of oncology, 2023-08, Vol.34 (8), p.670-680

2023

Volltextzugriff (PDF)

NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells

International journal of oncology, 2017-11, Vol.51 (5), p.1553-1562

2017

Volltextzugriff (PDF)

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Biochemical pharmacology, 2022-10, Vol.204, p.115228-115228, Article 115228

2022

Volltextzugriff (PDF)

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

European journal of pharmacology, 2024-08, Vol.977, p.176725, Article 176725

2024

Volltextzugriff (PDF)

HER3 in cancer: from the bench to the bedside

Journal of experimental & clinical cancer research, 2022-10, Vol.41 (1), p.1-310, Article 310

2022

Volltextzugriff (PDF)

Beyond HER2: Targeting the ErbB receptor family in breast cancer

Cancer treatment reviews, 2022-09, Vol.109, p.102436-102436, Article 102436

2022

Volltextzugriff (PDF)

Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling

Breast cancer research : BCR, 2004-03, Vol.6 (3), p.R246-R246, Article R246

2004

Volltextzugriff (PDF)

Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells

Experimental cell research, 2018-05, Vol.366 (1), p.34-40

2018

Volltextzugriff (PDF)

Fabrication and investigation potential effect of lentinan and docetaxel nanofibers for synergistic treatment of breast cancer in vitro

Polymers for advanced technologies, 2022-05, Vol.33 (5), p.1468-1480

2022

Volltextzugriff (PDF)

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Cancer cell, 2021-08, Vol.39 (8), p.1099-1114.e8

2021

Volltextzugriff (PDF)

The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer

Cancer letters, 2016-09, Vol.380 (1), p.20-30

2016

Volltextzugriff (PDF)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Cancer reports, 2024-03, Vol.7 (3), p.e1954-n/a

2024

Volltextzugriff (PDF)

Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1

Cancers, 2021-02, Vol.13 (4), p.871

2021

Volltextzugriff (PDF)

HER3 signaling and targeted therapy in cancer

Oncology Reviews, 2018-05, Vol.12 (1), p.355-355

2018

Volltextzugriff (PDF)

Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

Cancer, 2024-04, Vol.130 (S8), p.1392-1402

2024

Volltextzugriff (PDF)

A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance

Breast cancer research : BCR, 2024-06, Vol.26 (1), p.1-16, Article 107

2024

Volltextzugriff (PDF)

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer

Molecular carcinogenesis, 2024-08, Vol.63 (8), p.1528-1541

2024

Volltextzugriff (PDF)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

EMBO molecular medicine, 2020-05, Vol.12 (5), p.e11498-n/a

2020

Volltextzugriff (PDF)

HER3 receptor and its role in the therapeutic management of metastatic breast cancer

Journal of translational medicine, 2024-07, Vol.22 (1), p.665-15, Article 665

2024

Volltextzugriff (PDF)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

Molecular therapy. Nucleic acids, 2018-03, Vol.10, p.317-330

2018

Volltextzugriff (PDF)

1 – 25 von 124

Suche als RSS-Feed

Aktive Filter

ThemaBreast Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(117)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Trastuzumab: updated mechanisms of action and resistance in breast cancer

Long road towards effective HER3 targeting in breast cancer

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

HER3 in cancer: from the bench to the bedside

Beyond HER2: Targeting the ErbB receptor family in breast cancer

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling

Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells

Fabrication and investigation potential effect of lentinan and docetaxel nanofibers for synergistic treatment of breast cancer in vitro

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1

HER3 signaling and targeted therapy in cancer

Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer

Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

HER3 receptor and its role in the therapeutic management of metastatic breast cancer

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

Aktive Filter

Suchergebnisse filtern